Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $20.50 Consensus PT from Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) has earned an average rating of “Buy” from the four research firms that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have covered the stock in the last […]

Related Keywords

Canada ,Ohio ,United States ,Japan ,China ,Mexico ,American ,Craig Hallum ,American Century Companies Inc ,Institutional Trading Of Ironwood Pharmaceuticals ,News Ratings For Ironwood Pharmaceuticals Daily ,Jefferies Financial Group ,Walleye Capital ,Nasdaq ,Vanguard Group Inc ,Wells Fargo Company ,Ironwood Pharmaceuticals ,Ironwood Pharmaceuticals Inc ,Raymond James Financial Services Advisors Inc ,Ironwood Pharmaceuticals Stock ,Get Free Report ,Marketbeat Ratings ,Financial Group ,James Financial Services Advisors ,Employees Retirement System ,Century Companies ,Get Free ,Ironwood Pharmaceuticals Daily ,Nasdaq Irwd ,Irwd ,Medical ,46333x10 ,Ratings ,Consensus ,